Cirrhosis
Noninvasive model minimizes the risk for missing high-risk varices in unresectable HCC
A model using both clinical and imaging data predicted the absence of high-risk varices in patients with unresectable hepatocellular carcinoma and may help avoid unnecessary upper endoscopy in low-risk patients, research showed.
FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis
Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.
Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC
A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.
Prevalence of cirrhosis ‘more than double’ in transgender vs. cisgender adults
Transgender adults had “more than double” the prevalence of cirrhosis vs. cisgender adults, as well as higher rates of comorbidities linked to liver disease progression, researchers reported in The American Journal of Gastroenterology.
Up to 13% with dementia may instead have ‘treatable’ HE due to undiagnosed cirrhosis
Up to 13% of patients with dementia have lab values that suggest undiagnosed cirrhosis and possible hepatic encephalopathy, an “easily treatable” cause of cognitive impairment, according to a study in The American Journal of Medicine.
‘It’s time for action’: World Hepatitis Day calls to end an ‘entirely preventable disease’
Every year on July 28th, clinicians and researchers recognize World Hepatitis Day to bring awareness to one of the world’s deadliest but preventable viruses and continue efforts to meet the global goal of eliminating viral hepatitis by 2030
‘Even one meal change’ to vegetarian, vegan can reduce serum ammonia in cirrhosis
Substitution of just one meat-based meal with a vegetarian or vegan alternative reduced serum ammonia levels for up to 3 hours and improved metabolites in patients with cirrhosis who follow a Western meat-based diet, researchers reported.
Survodutide may have ‘positive effects on patient’s liver status’ in MASH cirrhosis
Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis, with no dose reduction needed based on pharmacokinetics, according to data.
Research highlights ‘serious unmet need’ for LT in severe acute-on-chronic liver failure
Interim results from a global, multicenter study demonstrated the benefit of liver transplantation among patients with acute-on-chronic liver failure grades 2 and 3 and suggest that current allocation systems are inadequate.
Bulevirtide monotherapy ‘may prevent decompensation but not HCC’ in HDV, cirrhosis
Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients.